Core Viewpoint - The company Bai Aosaitu-B (02315) has experienced a significant stock price increase of over 5%, attributed to strong financial performance and ongoing expansion in overseas markets [1] Financial Performance - For the fiscal year 2025, the company expects to achieve a revenue of approximately 1.379 billion RMB, representing a year-on-year growth of 40.63% [1] - The net profit attributable to the owners of the company is projected to be 173 million RMB, reflecting a remarkable year-on-year increase of 416.37% [1] - The net profit after deducting non-recurring gains and losses is anticipated to be 116 million RMB, with a year-on-year growth of 405.39% [1] Asset and Equity Growth - The total assets of the company are expected to reach 3.724 billion RMB, an increase of 54.20% compared to the beginning of the period [1] - The equity attributable to the owners of the company is projected to be 2.175 billion RMB, showing a substantial increase of 160.76% from the start of the period [1] Strategic Drivers - The growth in operating performance is primarily driven by the continuous expansion into overseas markets, alongside a recovery in the domestic biopharmaceutical industry [1] - The company emphasizes an innovation-driven strategy, maintaining high levels of research and development investment to build core technological barriers and ensure stable high gross margins [1] - Lean management practices are being implemented to continuously enhance operational efficiency, contributing to rapid improvements in profitability [1]
港股异动 再涨超5% 预计去年归母净利同比增长416.37% 海外市场持续拓展